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740 The Journal of Thoracic and CardioObjectives: The histone deacetylase inhibitor suberoylanilide hydroxamic acid
induces apoptosis in some malignancies through mitochondrial injury and genera-
tion of reactive oxygen species. Histone deacetylase inhibitors also activate the
antiapoptotic transcription factor nuclear factor B. We hypothesize that protea-
some inhibition with bortezomib (Velcade; Millennium Pharmaceuticals, Inc,
Cambridge, Mass) will inhibit nuclear factor B activation, enhance suberoylanilide
hydroxamic acid–induced mitochondrial injury, and sensitize non–small cell lung
cancer cells to apoptosis.
Methods: Four tumorigenic non–small cell lung cancer cell lines were treated with
nothing, suberoylanilide hydroxamic acid, bortezomib, or both drugs. Nuclear factor
B–dependent transcription was determined by reporter gene assays and endoge-
nous interleukin 8 transcription. Reactive oxygen species were quantified by using
the fluorophore H2DCFDA. Cell viability was determined on the basis of clonogenic
survival, and apoptosis was measured by quantifying caspase-3 activity and DNA
fragmentation. Apoptosis and cell-survival assays were repeated in similarly treated
cells incubated in the presence or absence of N-acetyl cysteine. Statistical signifi-
cance was determined by means of analysis of variance.
Results: Suberoylanilide hydroxamic acid significantly enhanced interleukin 8 and
nuclear factor B–dependent reporter gene transcription, and these effects were
inhibited by bortezomib (P  .01). Combined treatment with suberoylanilide
hydroxamic acid and bortezomib induced greater reactive oxygen species genera-
tion, more apoptosis (P  .02), and more cell death (P  .001) than either drug
alone. N-acetyl cysteine diminished the induction of apoptosis and enhanced cell
survival (P  .04).
Conclusions: Suberoylanilide hydroxamic acid and bortezomib synergistically in-
duce reactive oxygen species generation in non–small cell lung cancer, and this
plays a critical role in the induction of apoptosis after treatment. Combined treat-
ment with suberoylanilide hydroxamic acid and bortezomib might be an effective
treatment strategy for non–small cell lung cancer.
Non–small cell lung cancer (NSCLC) remains resistant tochemotherapy-induced apoptosis, despite the advent of third-generation chemotherapeutic agents.1,2 Although the moleculartargets of different chemotherapies are diverse, the efficacy of allagents depends on exploitation of the endogenous apoptotic ma-chinery. Histone deacetylase inhibitors (HDIs), which induce
differentiation, cell-cycle arrest, and apoptosis in some malignancies, are only
moderately efficacious in NSCLC, and this relates in part to the activation of the
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B).3-5 NF-B promotes cell survival after exposure to
chemotherapy by driving the transcription of genes that
antagonize the apoptotic cascade at multiple levels.6-8
Two well-established apoptotic pathways are the extrin-
sic pathway, which is initiated by ligands binding their
respective cell-surface receptors, and the intrinsic pathway,
which is mediated through enhanced mitochondrial perme-
ability.9,10 Nuclear stress signals resulting from DNA
damage converge on the mitochondria, permeabilize the
membrane, and allow the subsequent release of apoptosis-
inducing factor, cytochrome C, and other apoptogenic
proteins.11 In the presence of adenosine triphosphate, cyto-
chrome C binds Apaf-1 and procaspase-9, forming the ap-
optosome, which activates downstream effecter caspases
(caspase-3, caspase-6, and caspase-7), ultimately leading to
the morphologic changes of apoptosis.11 Suberoylanilide
hydroxamic acid (SAHA), an HDI well tolerated in phase I
and II clinical trials, has been shown to induce apoptosis
through the generation of reactive oxygen species (ROS)
and mitochondrial permeabilization.12-14 A recently delin-
eated mechanism underlying this phenomenon involves
acetylation and inactivation of Ku70, the endogenous inhib-
itor of the BH3-only protein Bax.15 Although HDIs induce
mitochondrial-mediated apoptosis through Bax disinhibi-
tion, they also activate cytoprotective pathways mediated
through NF-B in NSCLC.5 Thus simultaneous activation
of mutually antagonistic pathways likely contributes to the
limited efficacy of HDIs observed in vitro and in vivo in
NSCLC. We have recently shown that direct inhibition of
NF-B with a dominant negative IB, the endogenous
NF-B inhibitor, dramatically sensitized NSCLC to HDI-
induced apoptosis.5 Because IB is degraded by protea-
somes after phosphorylation and ubiquitination, we subse-
quently found that the US Food and Drug Administration–
approved proteasome inhibitor bortezomib (Velcade;
Millennium Pharmaceuticals, Inc, Cambridge, Mass) also
sensitized NSCLC to HDI-induced apoptosis.4
Proteasomes are protease complexes comprised of a
20S catalytic core and 2 regulatory 19S subunits.16
Proteasomes degrade cytoplasmic and nuclear proteins after
ubiquitination and play important roles in regulating eukary-
otic cellular processes, such as cell-cycle progression, gene
transcription, antigen processing, and degradation of transient
signaling molecules, including IB and Bcl-2 family pro-
teins.17-19 In addition to inhibiting transcription of anti-apop-
totic NF-B–regulated genes, bortezomib also facilitates accu-
mulation of the proapoptotic proteins Bax, Bad, and Bak,
which collectively injure mitochondria and enhance ROS gen-
eration.20,21 Proteasomes can be inhibited endogenously, and
this has been implicated in a self-perpetuating feed-forward
cycle leading to apoptosis, in which caspase-3 inhibits protea-
some function, leading to subsequent mitochondrial injury and
The Journal of Thoracicytochrome C release, which further activates caspase-3.16
Thus normal proteasome function is critical for protecting cells
from mitochondrial-mediated apoptosis.
The purpose of this study was to determine whether
combined treatment with the HDI SAHA and the protea-
some inhibitor bortezomib would induce apoptosis in
NSCLC through increased mitochondrial permeability, en-
hanced generation of ROS, and inhibition of NF-B–
dependent transcription.
Methods
Cell-Culture Reagents and Plasmids
Four tumorigenic NSCLC lines (NCI-H157, NCI-H358, NCI-
H460, and NCI-A549) obtained from the American Type Culture
Collection were cultured in RPMI-1640 (Invitrogen, Carlsbad,
Calif) supplemented with 10% fetal bovine serum (HyClone Lab-
oratories, Logan, Utah) and penicillin-streptomycin. The 3x-B
luciferase (3x-B Luc) reporter construct contains NF-B DNA-
binding consensus sites originally identified in the major histo-
compatability complex class I promoter and inserted upstream to
firefly luciferase. Antibodies against cytochrome C and -tubulin
were obtained from Pharmingen (San Diego, Calif) and Sigma (St
Louis, Mo), respectively. SAHA was purchased from Biomol
(Plymouth Meeting, Pa), bortezomib was kindly provided by
Millennium Pharmaceuticals, and N-acetyl cysteine (NAC) was
purchased from Calbiochem (La Jolla, Calif).
Cell Viability Assays
NSCLC cells at 75% confluency were treated with either nothing
or SAHA (5 mol/L) for 0, 24, 48, or 72 hours. In another
experiment cells were treated with nothing, SAHA and bort-
ezomib, or SAHA, bortezomib, and NAC concomitantly for 36
hours. Cell viability was then determined by sequentially incubat-
ing the cells in 1% glutaraldehyde and 0.5% crystal violet for 15
minutes each. The cells were thoroughly washed and dried, and the
dye was eluted with Sorenson solution (30 mmol/L sodium citrate,
0.02 mol/L HCl, and 50% ethanol) at room temperature for 15
minutes. The optical density of the eluent was measured at a
wavelength of 570 nm.
Luciferase Reporter Gene Assays
NSCLC cells were transfected with 3x-B Luc (0.5 g/well) with
Polyfect (Qiagen, Valencia, Calif), according to the manufactur-
er’s instructions. Six hours after transfection, additional medium
was added containing the appropriate pharmacologic agents. After
treatment for 18 hours, cells were washed with phosphate-buffered
saline and lysed in luciferase reporter buffer (Promega, Madison,
Wis). Cells were sequentially snap-frozen at80°C and thawed at
37°C. Cell lysates were cleared by means of centrifugation at
13,000g, and protein concentrations were determined with the
Pierce BCA protein assay kit (Pierce, Rockford, Ill). Luciferase
assays were performed with the substrate D-Luciferin, and relative
light units were measured with an AutoLumat LB953 luminometer
(Berthold Analytical Instruments, Pforzheim, Germany). Lumines-
cence was normalized to protein concentrations.
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NCSLC cells were treated with nothing, SAHA (5 mol/L), bort-
ezomib (50 nmol/L), or both compounds for 24 hours. Mitochondria-
free cytoplasmic extracts were prepared by resuspending pelleted cells
in 5 pellet volumes of buffer A (250 mmol/L sucrose, 20 mmol/L
N-2hydroxyethylpiperazine-N-2-ethanesulfonic acid [HEPES], 10
mmol/L KCl, 1.5 mmol/L MgCl2, 1 mmol/L ethylenediamine tet-
raacetic acid, 1 mmol/L dithiothreitol, and 0.1 mmol/L phenylmeth-
ylsulfonyl fluoride) and incubated on ice for 30 minutes. Cells were
homogenized with a Teflon rod before centrifugation at 16,000g for
30 minutes. Cytoplasmic extracts (45 g/lane) were resolved by
SDS-PAGE and transferred to nitrocellulose membranes. Primary
antibodies against cytochrome C and -tubulin were used for immu-
noblotting.
Reverse Transcription–Polymerase Chain Reaction
NCSLC cells were treated for 12 hours under previously described
experimental conditions. Cells were lysed with Trizol (Invitrogen),
and proteins were extracted with chloroform. RNAs were precip-
itated with isopropanol and washed with 70% ethanol. cDNAs
were created by using the Advantage RT for PCR enzyme
(Clontech, Palo Alto, Calif), and interleukin 8 (IL8) cDNA was
amplified by means of PCR with Platinum Taq (Invitrogen) and
the primers 5=-CTTCCAAGCTGGCCGTGG-3= and 5=-TGAAT-
TCTCAGCCTTCTT-3=. As a control, GAPDH cDNA was ampli-
fied by using the primers 5=-GTGAGGAGGGGAGATTCAG-3=
and 5=-GCATCCTGGGCTACACTG-3=. Polymerase chain reac-
tion products were resolved on a 0.8% agarose gel.
Apoptosis Assays
NSCLC cells were plated at 5  105 cells per well on 12-well
plates. Twelve hours after plating, cells were either left alone or
treated with SAHA, bortezomib, or both drugs. After 24 hours of
treatment, cells were harvested, and apoptosis was quantified by
means of detection of caspase-3 activation and DNA fragmenta-
tion. Caspase-3 activity was determined by the addition of an
APC-DEVD protein conjugate (Calbiochem) to cellular lysates
containing 25 g of protein. Fluorescence of caspase-3–cleaved
protein conjugates was determined fluorometrically. DNA frag-
mentation was determined by means of evaluation of cellular
nucleosome formation with the Cell Death Detection ELISA Plus
kit (Roche, Indianapolis, Ind), according to the manufacturer’s
instructions.
Measurement of Mitochondrial Membrane Potential
and ROS Generation
Cells were treated for 24 hours with the appropriate agents before
incubation with 1 nmol/L 3=3=-dihexyloxacarboxyanine iodide
(DiOC6[3]; Molecular Probes, Eugene, Ore) at 37°C for 15 min-
utes and harvesting by means of trypsinization. Cells were washed
3 times with ice-cold phosphate-buffered saline, and mitochondrial
membrane potential (m) was determined by means of flow
cytometry. ROS were measured by incubating trypsinized cells
with H2DCFDA (Molecular Probes) at 22°C for 15 minutes in
HEPES-buffered saline before analysis by means of flow cytom-
etry.
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Thinly plated NSCLC cells were treated as described previously.
After a 24-hour treatment period, cells were washed, and the
drug-containing media was replaced with fresh media. Clonogenic
cell survival was determined by allowing cells to grow for an
additional week after treatment. Colonies were stained with crystal
violet as previously described.
Statistical Analysis and Data Interpretation
Where appropriate, statistical significance was determined by means
of analysis of variance and post-hoc analysis with Bonferroni tests.
The study design, data analysis, and interpretation, as well as the
decision to submit this article for publication, were not influenced by
any outside funding agency.
Results
SAHA Induces Minimal Apoptosis and Cell Death in
NSCLC
Despite promising results in preclinical studies with SAHA
in prostate and breast cancer, as well as other malignancies,
less dramatic results were appreciated in early-phase clini-
cal trials.12 To determine whether SAHA induces apoptosis
in NSCLC, 4 tumorigenic NSCLC cell lines were treated
with a clinically relevant dose of SAHA (5 mol/L) for 24
hours.12 SAHA did not significantly induce apoptosis in any
cell line in this short-term apoptosis assay (data not shown).
Mitsiades and colleagues22 recently indicated that although
cells are irreversibly committed to apoptosis within a few
hours of exposure to SAHA, execution of apoptosis actually
occurs as a significantly delayed event. Therefore to deter-
mine whether SAHA induces NSCLC cell death after pro-
longed exposure, cells was incubated in the presence of
SAHA for up to 72 hours. In contrast to previous reports,
only marginal diminutions in NSCLC survival were ob-
served after prolonged treatment (data not shown). These
data suggest that NSCLC does not respond dramatically to
SAHA-induced proapoptotic signals previously demon-
strated in other models.
SAHA-Induced Activation of NF-B Is Suppressed by
Bortezomib
We and others have previously shown that the antiapoptotic
transcription factor NF-B is a key mediator of the resistance
of solid tumors, including NSCLC, to apoptosis.6,7,23 SAHA
enhanced NF-B–dependent transcription 8- to 20-fold, as
measured by the 3x-B reporter gene assay (Figure 1, A).
Because NF-B inhibition enhances the sensitivity of NSCLC
to HDI-induced apoptosis,4,5 cells were also treated with bort-
ezomib to determine whether bortezomib could suppress such
a dramatic activation of NF-B. As shown in Figure 1, A,
bortezomib suppressed both the basal and SAHA-induced
NF-B transcriptional activity, as measured by using the tran-
sient reporter gene (P  .01).
To determine whether SAHA and bortezomib have sim-
ilar effects on the transcription of endogenous genes, re-
mber 2004
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analysis was performed on NSCLC cells probing for IL8, a
gene tightly regulated by NF-B.5 SAHA dramatically up-
regulated IL8 transcription, and these effects were attenu-
ated by the addition of bortezomib (Figure 1, B), thus
confirming the result seen in Figure 1, A. Collectively, these
results demonstrate that SAHA activates NF-B and that
bortezomib suppresses SAHA-induced NF-B activity to
near basal levels.
Bortezomib Sensitizes NSCLC to SAHA-Induced
Apoptosis
Cells were treated for 24 hours with nothing, SAHA, bort-
ezomib, or both drugs to determine whether bortezomib would
sensitize NSCLC cells to SAHA-induced death. Neither
SAHA nor bortezomib alone significantly induced apoptosis
after treatment as single agents. Conversely, combined treat-
Figure 1. A, NSCLC cells were treated with nothin
transcriptional activity was determined with a transien
as noted in Figure 2, A, and transcription of the NF-B
†P < .01 and *P < .001, SAHA versus SAHA/bortezomment with both SAHA and bortezomib enhanced DNA frag-
The Journal of Thoracimentation (P  .02) and caspase-3 activation (P  .01) rela-
tive to all of the other treatment conditions (Figure 2, A and B).
To quantify cell death in absolute terms, clonogenic
survival assays were performed. As shown in Figure 2, C
and D, combined treatment with SAHA and bortezomib
killed 71% to 99% of the cells compared with the other
treatment groups (P  .001; Figure 2, D). Because these
dramatic results hold promise for further studies in vivo
or potentially in phase I clinical trials, subsequent clo-
nogenic survival studies were performed to determine
whether concomitant or sequential treatment was more
efficacious. A549 cells were treated with SAHA and
bortezomib for 24 hours each, and the drugs were admin-
istered either sequentially (SAHA followed by bort-
ezomib or in the reverse order) or concomitantly. This
study indicated that concomitant therapy was the most
efficacious strategy (data not shown). Taken together,
AHA, bortezomib, or both drugs. NF-B– dependent
ferase reporter gene assay. B, H358 cells were treated
endent gene IL8 was determined by means of RT-PCR.g, S
t luci
– depthese data suggest that the combined therapy of SAHA
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death in NSCLC and that concomitant administration is
the most efficacious strategy in vitro.
SAHA and Bortezomib Induce Mitochondrial Damage
and ROS Release
Because both SAHA and bortezomib have been shown to
enhance ROS generation and mitochondrial injury, experi-
ments were performed to address whether combined treat-
ment with SAHA and bortezomib further enhanced ROS
generation. As shown in Figure 3, A, isolated treatment with
Figure 2. NSCLC cells were treated with nothing, SAH
means of DNA fragmentation (A) and caspase-3 act
bortezomib, or both drugs, and clonogenic survival assay
as relative survival compared with that seen in untreateeither SAHA or bortezomib minimally enhanced ROS pro-
744 The Journal of Thoracic and Cardiovascular Surgery ● Noveduction in NSCLC. However, combined treatment with both
drugs induced more ROS than all other groups.
ROS generation during apoptosis has been associated
with loss of m.24 Treatment with either SAHA or bort-
ezomib alone slightly increased m. Additionally, com-
bined treatment-enhanced m did not cause any meaning-
ful m perturbations beyond what was observed with either
drug alone (Figure 3, B). Similarly, we did not observe any
significant changes in m in any of the treatment condi-
tions when cells were stained with JC-1, an unrelated stain
that differentially fluoresces on the basis of the presence of
ortezomib, or both drugs. Apoptosis was measured by
(B). NSCLC cells were treated with nothing, SAHA,
re performed (C). Colonies were counted and expressed
trol subjects (D). †P < .02; *P < .01; §P < .001.A, b
ivity
s weintact m (data not shown).
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evaluated NSCLC cells for cytochrome C extravasation
by means of Western blot analysis in mitochondrial-free
cytoplasmic extracts. As shown in Figure 3, C, minimal
cytochrome C was detected in the cytoplasm of untreated
cells or cells treated with either SAHA or bortezomib as
single agents. However, combined therapy with both
SAHA and bortezomib significantly enhanced cyto-
chrome C extravasation. Therefore the combined treat-
ment synergistically enhanced mitochondrial permeabil-
ity and cytochrome C extravasation, despite maintaining
a normal electrochemical potential gradient across the
Figure 3. NSCLC cells were treated with nothing, SAHA
was determined by using the ROS-sensitive fluoresc
(m) was measured by analyzing fluorescent spectra
extravasation from the mitochondria was determinedmitochondrial membrane.
The Journal of ThoraciN-acetyl Cysteine Rescues NSCLC from SAHA/
Bortezomib-Induced Apoptosis
ROS have previously been described as mediators in the
apoptotic cascade, as well as activators of NF-B, which
could explain a potential mechanism by which SAHA ac-
tivates NF-B. Experiments were performed to determine
whether administration of the free radical scavenger NAC
would inhibit SAHA-induced NF-B activation and
whether NAC could rescue NSCLC from apoptosis induced
by SAHA and bortezomib. NSCLC cells were treated with
nothing or SAHA in the presence or absence of NAC, and
NF-B–dependent transcription was measured with the
tezomib, or both drugs for 24 hours. A, Presence of ROS
tain H2DCFDA. B, Mitochondrial membrane potential
ts of the DiOC6 stain after treatment. C, Cytochrome C
eans of Western blot analysis., bor
ent s
l shif
by m3x-B Luc reporter construct. As seen previously, SAHA
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only moderately attenuated by the addition of NAC (Figure
4, A). This suggests that ROS have little or no role in
SAHA-induced NF-B activation.
Cells were treated with nothing, SAHA and bortezomib,
or SAHA, bortezomib, and NAC concomitantly to deter-
mine whether NAC would rescue NSCLC cells from
SAHA/bortezomib-induced apoptosis. NAC significantly
diminished apoptosis induced by the combined therapy (P
 .04; Figure 4, B). In a separate experiment cell-survival
assays were performed after similar treatment conditions to
confirm that changes in apoptosis translated to cell survival.
Figure 4. NSCLC cells were treated with nothing,
NF-B– dependent transcription was determined by u
measured by means of DNA fragmentation (B), and cell
*P < .04.Combined treatment with SAHA and bortezomib nearly
746 The Journal of Thoracic and Cardiovascular Surgery ● Noveeradicated cells; however, NAC enhanced cell survival in a
dose-dependent fashion. This suggests that the apoptosis
induced by SAHA and bortezomib is dependent, at least in
part, on the generation of ROS.
Discussion
The continued dismal survivals for patients with NSCLC
have recently been tempered by the introduction and con-
comitant enthusiasm for several molecularly targeted treat-
ment strategies. Despite the preclinical promise of these
novel agents, the clinical results have been sobering with
single therapy alone, regardless of the treatment or its in-
and bortezomib, or SAHA, bortezomib, and NAC.
the 3x-B reporter gene assay (A). Apoptosis was
ival was determined by staining with crystal violet (C).SAHA
sing
survtended molecular target. With improved understanding of
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ciation that multiple molecularly targeted therapies might be
more efficacious than single-agent therapy.
The data presented in this article build on previous work
by our group,4 which explores the preclinical merit of
combining histone deacetylase and proteasome inhibitors.
The genesis of this line of investigation is based on our
interest in HDIs, the antiapoptotic transcription factor NF-
B, and its role in modulating tumor cell death in NSCLC.
There was little cell death induced by single-agent therapy
(ie, SAHA) alone, regardless of the length of treatment time.
This observation is supported by previous work from our
group with other classes of HDIs, including butyrate and
trichostatin A.5 Although there are several plausible expla-
nations for this, one explanation is that SAHA activates
tumor cell-survival signal-transduction pathways, most no-
tably NF-B. As shown in Figure 1, SAHA induces NF-B
transcriptional activity, and bortezomib completely amelio-
rates this effect. Moreover, this combined therapy resulted
in markedly enhanced apoptotic cell death, as shown in
Figure 2. We and others have demonstrated that bortezomib
inhibits NF-B transcriptional activity and sensitizes
NSCLC to chemotherapy and sodium butyrate.4,25 Thus it
was not surprising to see a similar effect in this model
system. It was interesting that there appeared to be more cell
death with combined SAHA and bortezomib therapy com-
pared with that seen in our previous study evaluating bu-
tyrate and bortezomib.4
Several authors have demonstrated that HDI therapy
results in appreciable ROS generation.14,21 As shown in
Figure 3, A, SAHA/bortezomib-induced apoptosis corre-
lated with enhanced ROS generation. In agreement with
other studies,14,21 we also found that ROS generation was
present when either SAHA or bortezomib were used as
single agents, although not as much as with combined
therapy. ROS have been previously described as critical
second messengers for NF-B activation.26,27 ROS typi-
cally activate NF-B after receptor mediator–induced nu-
clear translocation of NF-B.26 In this study ROS did not
result in SAHA-induced NF-B activation given the fact
that NAC failed to block SAHA-mediated induction of
NF-B (Figure 4, A). In fact, the primary signaling mech-
anism through which HDIs appear to activate NF-B is by
enhancing its transactivation potential rather than inducing
its nuclear translocation.5 Therefore although SAHA did
induce low levels of ROS production (Figure 3, A) and
activate NF-B–dependent transcription (Figure 1), these
effects appear to be unrelated.
It is interesting that despite the increased production of ROS
with this combined treatment strategy, there was preservation
of the m. Two predominant but opposing theories on mito-
chondrial membrane permeability and cytochrome C extrava-
sation during the induction of apoptosis exist.11 One theory,
The Journal of Thoracifirst described in ischemia-reperfusion injury, is based on the
development of a permeability transition pore that opens under
conditions of oxidative stress, high Ca2, or low adenosine
triphosphate. The open pore allows influx of low-molecular-
weight solutes, leading to mitochondrial swelling, rupture, and
leakage of cytochrome C. The second theory relating to cyto-
chrome C extravasation during apoptosis contends that Bax
and other proapoptotic Bcl-2 member proteins polymerize and
insert into the outer mitochondrial membrane and allow cyto-
chrome C extravasation without disrupting mitochondrial
function or the m. These events lead to apoptosis in cells
capable of forming the apoptosome but also lead to necrosis in
cells not able to form the apoptosome because of the eventual
cytochrome C depletion within the mitochondria. Data pre-
sented in this article support the latter theory, in which cyto-
chrome C extravasation and apoptosis was observed in the
absence of significant changes in m (Figures 2 and 3).
A limitation of this study is that these studies are in vitro
experiments, and the results need to be replicated in vivo.
However, given the mechanistic nature of this study involving
ROS generation and the induction of apoptosis in an ROS-
dependent manner, repeated studies in vivo would be signifi-
cantly more difficult to validate this proposed mechanism of
action for the combined therapy. Additionally, this study is
based on use of a single HDI and a single proteasome inhibitor.
Other agents might have resulted in different results. We chose
SAHA and bortezomib on the basis of the fact that they
represent the most clinically relevant agents currently in their
respective drug classes.
In conclusion, this study demonstrates that combined
SAHA and bortezomib induces apoptosis in NSCLC and that
the interaction between these drugs is mediated in part through
the generation of ROS and enhanced mitochondrial permeabil-
ity. Because both of these agents are being evaluated individ-
ually in clinical trials, consideration of combining these com-
pounds in future phase I trials appears warranted.
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Dr W. Roy Smythe (Temple, Tex). I enjoyed your talk. As you know,
NF-B actually is a transcriptional regulator of a number of genes that
all have growth importance in propagation of the neoplastic pheno-
type. A few years back, in our laboratory, we combined a different
proteasome inhibitor with sodium butyrate and saw similar effects,
although obviously butyrate is not as clinically relevant as SAHA. But
interestingly enough, when we looked at Bcl-XL expression, even
though we saw an effect of the proteasome inhibitor on NF-B, we
did not see a compensatory change in Bcl-XL expression, which
made the whole paradigm a little bit more questionable.
Did you look at downstream mediators of NF-B? Did you
look at Bcl-XL and phosphatidylinositol 3-kinase, downstream
mediators of NF-B, in this series of experiments?
Dr Denlinger. Yes, we did. We did look at Bcl-xL expression
using RT-PCR and found what you found: very little induction by
SAHA or, conversely, repression by bortezomib. Therefore at present,
we are not certain what downstream effectors we are affecting, despite
our findings that combined therapy does result in significant apoptosis.
Dr Dao M. Nguyen (Bethesda, Md). I really enjoyed your talk.
I have been following your work in the last few years.
I have a few questions for you. Number one, have you looked at
the time course, the kinetic of the ROS generation, and what time after
the combination treatment you start seeing the increase in ROS
generation?
Dr Denlinger. All of the experiments performed, with the excep-
tion of one, were conducted at 24-hour delays after treatment. There-
fore we evaluated ROS and cytochrome c extravasation after 24 hours
of concomitant treatment with SAHA and bortezomib.
Dr Nguyen. So you think the ROS is coming from mitochondria?
Dr Denlinger. There are conflicting reports in the literature
suggesting whether it precedes or follows mitochondrial injury. I
think in our model it comes after mitochondrial injury.
Dr Nguyen. Did you try to block the mitochondrial function by
overexpressing Bcl-2 to see whether you can abrogate this effect
and abrogate the ROS generation, or do you think that the ROS
provides a positive feedback loop that keeps on destroying the
mitochondria and makes the cells totally committed to death?
Dr Denlinger. We have not tried overexpression of antiapop-
totic proteins, such as Bcl-2, Bcl-XL, or Bfl/A1. Again, we believe
that ROS generation occurs from mitochondria, but we have not
evaluated the feedback loop.
Dr Jack Roth (Houston, Tex). Is this effect selective for cancer
cells, or do you also see this in some normal cell populations that
you treat with the combination?
Dr Denlinger. We have not evaluated this combination in a
noncancerous cell line. We have looked at the combination of
sodium butyrate, a different HDI, with bortezomib in animals and
saw very little overt toxicity in the mice.
Dr Thomas A. D’Amico (Durham, NC). Chad, that was beauti-
ful. Is your next step an animal model, and which model will you use?
Dr Denlinger. We would love to continue this study in an animal
model, and if we would do this, we would probably generate xeno-
grafts with the A549 cell line on the basis of our prior experience. Our
limitation currently is gaining access to adequate quantities of the
compounds. We prefer using clinically relevant compounds, but the
downside of that is that they are often difficult to acquire in adequate
supplies to do the in vivo studies.
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